Infection and chronic allograft dysfunction

Kidney International

Volumn 78, Issue SUPPL. 119, 2010, Pages

  Dupont, Peter J ^a   Manuel, Oriol ^b   Pascual, Manuel ^b  

^a ROYAL FREE HOSPITAL   (United Kingdom)

^b UNIVERSITY OF LAUSANNE   (Switzerland)

Author keywords

BK virus; chronic allograft dysfunction; cytomegalovirus; infection; urinary tract infection

Indexed keywords

ACUTE GRAFT REJECTION; ADENOVIRUS INFECTION; BACTERIAL INFECTION; CHRONIC ALLOGRAFT DYSFUNCTION; CHRONIC GRAFT REJECTION; CONFERENCE PAPER; CRYOGLOBULINEMIA; CYTOMEGALOVIRUS INFECTION; CYTOTOXICITY; DISEASE ASSOCIATION; DNA VIRUS INFECTION; EPSTEIN BARR VIRUS; GRAFT FAILURE; HEPATITIS C; HUMAN; KIDNEY DISEASE; LYMPHOPROLIFERATIVE DISEASE; NONHUMAN; PARVOVIRUS INFECTION; POLYOMA VIRUS; POLYOMAVIRUS INFECTION; PRIORITY JOURNAL; URINARY TRACT INFECTION;

EID: 78649639544     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2010.423     Document Type: Conference Paper

References (111)

1. Hariharan S, Johnson CP, Bresnahan BA et al. Improved graft survival after renal transplantation in the United States, 1988 to 1996. N Engl J Med 2000; 342: 605-612.
2. Denton MD, Magee CC, Sayegh MH. Immunosuppressive strategies in transplantation. Lancet 1999; 353: 1083-1091.
3. Kaneku HK, Terasaki PI. Thirty year trend in kidney transplants: UCLA and UNOS Renal Transplant Registry. Clin Transpl 2006: 1-27.
4. Pascual M, Theruvath T, Kawai T et al. Strategies to improve long-term outcomes after renal transplantation. N Engl J Med 2002; 346: 580-590. (Pubitemid 34438820)
5. Gardner SD, Field AM, Coleman DV et al. New human papovavirus (B.K.) isolated from urine after renal transplantation. Lancet 1971; 1: 1253-1257.
6. Hirsch HH. Polyomavirus BK nephropathy: a (re-)emerging complication in renal transplantation. Am J Transplant 2002; 2: 25-30.
7. Pappo O, Demetris AJ, Raikow RB et al. Human polyoma virus infection of renal allografts: histopathologic diagnosis, clinical significance, and literature review. Mod Pathol 1996; 9: 105-109.
8. Binet I, Nickeleit V, Hirsch HH et al. Polyomavirus disease under new immunosuppressive drugs: a cause of renal graft dysfunction and graft loss. Transplantation 1999; 67: 918-922.
9. Ramos E, Drachenberg CB, Portocarrero M et al. BK virus nephropathy diagnosis and treatment: experience at the University of Maryland Renal Transplant Program. Clin Transpl 2002: 143-153.
10. Rahamimov R, Lustig S, Tovar A et al. BK polyoma virus nephropathy in kidney transplant recipient: the role of new immunosuppressive agents. Transplant Proc 2003; 35: 604-605.
11. Nickeleit V, Klimkait T, Binet IF et al. Testing for polyomavirus type BK DNA in plasma to identify renal-allograft recipients with viral nephropathy. N Engl J Med 2000; 342: 1309-1315.
12. Lipshutz GS, Flechner SM, Govani MV et al. BK nephropathy in kidney transplant recipients treated with a calcineurin inhibitor-free immunosuppression regimen. Am J Transplant 2004; 4: 2132-2134.
13. Ghafari A, Lessan-Pezeshki M, Taghizadieh M et al. BK polyoma virus nephropathy among Iranian renal transplant recipients. Transplant Proc 2008; 40: 193-195.
14. White LH, Casian A, Hilton R et al. BK virus nephropathy in renal transplant patients in London. Transplantation 2008; 85: 1008-1015.
15. Koukoulaki M, Grispou E, Pistolas D et al. Prospective monitoring of BK virus replication in renal transplant recipients. Transpl Infect Dis 2009; 11: 1-10.
16. Smith JM, Dharnidharka VR, Talley L et al. BK virus nephropathy in pediatric renal transplant recipients: an analysis of the North American Pediatric Renal Trials and Collaborative Studies (NAPRTCS) registry. Clin J Am Soc Nephrol 2007; 2: 1037-1042.
17. Kim HC, Hwang EA, Han SY et al. Polyomavirus nephropathy after renal transplantation: a single centre experience. Nephrology (Carlton) 2005; 10: 198-203.
18. Nickeleit V, Hirsch HH, Zeiler M et al. BK-virus nephropathy in renal transplants-tubular necrosis, MHC-class II expression and rejection in a puzzling game. Nephrol Dial Transplant 2000; 15: 324-332.
19. Weiss AS, Gralla J, Chan L et al. Aggressive immunosuppression minimization reduces graft loss following diagnosis of BK virus-associated nephropathy: a comparison of two reduction strategies. Clin J Am Soc Nephrol 2008; 3: 1812-1819.
20. Dall A, Hariharan S. BK virus nephritis after renal transplantation. Clin J Am Soc Nephrol 2008; 3(Suppl 2): S68-S75.
21. Bohl DL, Brennan DC. BK virus nephropathy and kidney transplantation. Clin J Am Soc Nephrol 2007; 2(Suppl 1): S36-S46.
22. Chen Y, Trofe J, Gordon J et al. Interplay of cellular and humoral immune responses against BK virus in kidney transplant recipients with polyomavirus nephropathy. J Virol 2006; 80: 3495-3505.
23. Smith JM, McDonald RA, Finn LS et al. Polyomavirus nephropathy in pediatric kidney transplant recipients. Am J Transplant 2004; 4: 2109-2117.
24. Ginevri F, De Santis R, Comoli P et al. Polyomavirus BK infection in pediatric kidney-allograft recipients: a single-center analysis of incidence, risk factors, and novel therapeutic approaches. Transplantation 2003; 75: 1266-1270.
25. Doucette KE, Pang XL, Jackson K et al. Prospective monitoring of BK polyomavirus infection early posttransplantation in nonrenal solid organ transplant recipients. Transplantation 2008; 85: 1733-1736.
26. Drachenberg CB, Papadimitriou JC, Mann D et al. Negative impact of human leukocyte antigen matching in the outcome of polyomavirus nephropathy. Transplantation 2005; 80: 276-278.
27. Awadalla Y, Randhawa P, Ruppert K et al. HLA mismatching increases the risk of BK virus nephropathy in renal transplant recipients. Am J Transplant 2004; 4: 1691-1696.
28. Viscount HB, Eid AJ, Espy MJ et al. Polyomavirus polymerase chain reaction as a surrogate marker of polyomavirus-associated nephropathy. Transplantation 2007; 84: 340-345.
29. Geramizadeh B, Roozbeh J, Malek-Hosseini SA et al. Urine cytology as a useful screening method for polyoma virus nephropathy in renal transplant patients: a single-center experience. Transplant Proc 2006; 38: 2923-2925. (Pubitemid 44737975)
30. Nolte FS. Case studies in cost effectiveness of molecular diagnostics for infectious diseases: pulmonary tuberculosis, enteroviral meningitis, and BK virus nephropathy. Clin Infect Dis 2006; 43: 1463-1467.
31. Lopez V, Gutierrez C, Burgos D et al. Prospective Study of Infection and Nephropathy Due to BK and JC Polyomavirus in 76 Kidney Transplant Recipients. Transplant Proc 2008; 40: 2927-2929.
32. Keller LS, Peh CA, Nolan J et al. BK transplant nephropathy successfully treated with cidofovir. Nephrol Dial Transplant 2003; 18: 1013-1014.
33. Cabello V, Margarit N, Diaz Pedrero M et al. Treatment of BK Virus-Associated Nephropathy With Cidofovir in Renal Transplantation. Transplant Proc 2008; 40: 2930-2932.
34. Lim WH, Mathew TH, Cooper JE et al. Use of cidofovir in polyomavirus BK viral nephropathy in two renal allograft recipients. Nephrology (Carlton) 2003; 8: 318-323.
35. Lamoth F, Pascual M, Erard V et al. Low-dose cidofovir for the treatment of polyomavirus-associated nephropathy: two case reports and review of the literature. Antivir Ther 2008; 13: 1001-1009.
36. Faguer S, Hirsch HH, Kamar N et al. Leflunomide treatment for polyomavirus BK-associated nephropathy after kidney transplantation. Transpl Int 2007; 20: 962-969.
37. Wu JK, Harris MT. Use of leflunomide in the treatment of polyomavirus BK-associated nephropathy. Ann Pharmacother 2008; 42: 1679-1685.
38. Drachenberg CB, Papadimitriou JC, Ramos E. Histologic versus molecular diagnosis of BK polyomavirus-associated nephropathy: a shifting paradigm? Clin J Am Soc Nephrol 2006; 1: 374-379.
39. Pang XL, Doucette K, LeBlanc B et al. Monitoring of polyomavirus BK virus viruria and viremia in renal allograft recipients by use of a quantitative real-time PCR assay: one-year prospective study. J Clin Microbiol 2007; 45: 3568-3573.
40. Cameron J, Rigby RJ, van Deth AG et al. Severe tubulo-interstitial disease in a renal allograft due to cytomegalovirus infection. Clin Nephrol 1982; 18: 321-325.
41. Birk PE, Chavers BM. Does cytomegalovirus cause glomerular injury in renal allograft recipients? J Am Soc Nephrol 1997; 8: 1801-1808.
42. Kashyap R, Shapiro R, Jordan M et al. The clinical significance of cytomegaloviral inclusions in the allograft kidney. Transplantation 1999; 67: 98-103.
43. Rao KV, Hafner GP, Crary GS et al. De novo immunotactoid glomerulopathy of the renal allograft: possible association with cytomegalovirus infection. Am J Kidney Dis 1994; 24: 97-103.
44. Cameron JM, Preston CM. Comparison of the immediate early polypeptides of human cytomegalovirus isolates. J Gen Virol 1981; 54: 421-424.
45. Beck S, Barrell BG. Human cytomegalovirus encodes a glycoprotein homologous to MHC class-I antigens. Nature 1988; 331: 269-272.
46. Garcia JF, Piris MA, Lloret E et al. p53 expression in CMV-infected cells: association with the alternative expression of the p53 transactivated genes p21/WAF1 and MDM2. Histopathology 1997; 30: 120-125.
47. Toyoda M, Galfayan K, Galera OA et al. Cytomegalovirus infection induces anti-endothelial cell antibodies in cardiac and renal allograft recipients. Transpl Immunol 1997; 5: 104-111.
48. Helantera I, Loginov R, Koskinen P et al. Persistent cytomegalovirus infection is associated with increased expression of TGF-beta1, PDGF-AA and ICAM-1 and arterial intimal thickening in kidney allografts. Nephrol Dial Transplant 2005; 20: 790-796.
49. Lowance D, Neumayer HH, Legendre CM et al. Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group. N Engl J Med 1999; 340: 1462-1470. (Pubitemid 29220545)
50. Opelz G, Dohler B, Ruhenstroth A. Cytomegalovirus prophylaxis and graft outcome in solid organ transplantation: a collaborative transplant study report. Am J Transplant 2004; 4: 928-936.
51. Couchoud C, Cucherat M, Haugh M et al. Cytomegalovirus prophylaxis with antiviral agents in solid organ transplantation: a meta-analysis. Transplantation 1998; 65: 641-647.
52. Hodson EM, Jones CA, Webster AC et al. Antiviral medications to prevent cytomegalovirus disease and early death in recipients of solid-organ transplants: a systematic review of randomised controlled trials. Lancet 2005; 365: 2105-2115.
53. Inkinen K, Soots A, Krogerus L et al. Cytomegalovirus infection enhances connective tissue growth factor mRNA expression in a rat model of chronic renal allograft rejection. Transplant Proc 2001; 33: 379.
54. Inkinen K, Holma K, Soots A et al. Expression of TGF-beta and PDGF-AA antigens and corresponding mRNAs in cytomegalovirus-infected rat kidney allografts. Transplant Proc 2003; 35: 804-805.
55. Helantera I, Teppo AM, Koskinen P et al. Increased urinary excretion of transforming growth factor-beta(1) in renal transplant recipients during cytomegalovirus infection. Transpl Immunol 2006; 15: 217-221.
56. Carlquist JF, Muhlestein JB, Horne BD et al. Cytomegalovirus stimulated mRNA accumulation and cell surface expression of the oxidized LDL scavenger receptor, CD36. Atherosclerosis 2004; 177: 53-59.
57. Reischig T, Jindra P, Hes O et al. Valacyclovir prophylaxis versus preemptive valganciclovir therapy to prevent cytomegalovirus disease after renal transplantation. Am J Transplant 2008; 8: 69-77.
58. Kliem V, Fricke L, Wollbrink T et al. Improvement in long-term renal graft survival due to CMV prophylaxis with oral ganciclovir: results of a randomized clinical trial. Am J Transplant 2008; 8: 975-983.
59. Meylan PR, Manuel O. Late-onset cytomegalovirus disease in patients with solid organ transplant. Curr Opin Infect Dis 2007; 20: 412-418.
60. Legendre C, Pascual M. Improving outcomes for solid-organ transplant recipients at risk from cytomegalovirus infection: late-onset disease and indirect consequences. Clin Infect Dis 2008; 46: 732-740.
61. Limaye AP, Bakthavatsalam R, Kim HW et al. Impact of cytomegalovirus in organ transplant recipients in the era of antiviral prophylaxis. Transplantation 2006; 81: 1645-1652.
62. Lamoth F, Manuel O, Venetz JP et al. What is the impact of late-onset cytomegalovirus disease after valganciclovir prophylaxis in kidney transplantation? Transplantation 2008; 86: 1323-1324.
63. Arthurs SK, Eid AJ, Pedersen RA et al. Delayed-onset primary cytomegalovirus disease and the risk of allograft failure and mortality after kidney transplantation. Clin Infect Dis 2008; 46: 840-846.
64. Hamshere RJ, Chisholm GD, Shackman R. Late urinary-tract infection after renal transplantation. Lancet 1974; 2: 793-794.
65. Hansen BL, Rohr N, Svendsen V et al. Bacterial urinary tract infection in cyclosporine-A immunosuppressed renal transplant recipients. Scand J Infect Dis 1988; 20: 425-427.
66. Prat V, Horcickova M, Matousovic K et al. Urinary tract infection in renal transplant patients. Infection 1985; 13: 207-210.
67. Abbott KC, Oliver III JD, Hypolite I et al. Hospitalizations for bacterial septicemia after renal transplantation in the United States. Am J Nephrol 2001; 21: 120-127. (Pubitemid 32453690)
68. Hibberd PL, Tolkoff-Rubin NE, Doran M et al. Trimethoprim- sulfamethoxazole compared with ciprofloxacin for the prevention of urinary tract infection in renal transplant recipients. A double-blind, randomized controlled trial. Online J Curr Clin Trials 1992; Doc No 15: [4083 words; 4046 paragraphs].
69. Karakayali H, Emiroglu R, Arslan G et al. Major infectious complications after kidney transplantation. Transplant Proc 2001; 33: 1816-1817.
70. Tolkoff-Rubin NE, Rubin RH. Urinary tract infection in the immunocompromised host. Lessons from kidney transplantation and the AIDS epidemic. Infect Dis Clin North Am 1997; 11: 707-717.
71. Rubin RH. Infectious disease complications of renal transplantation. Kidney Int 1993; 44: 221-236.
72. Pelle G, Vimont S, Levy PP et al. Acute pyelonephritis represents a risk factor impairing long-term kidney graft function. Am J Transplant 2007; 7: 899-907.
73. Giral M, Pascuariello G, Karam G et al. Acute graft pyelonephritis and long-term kidney allograft outcome. Kidney Int 2002; 61: 1880-1886.
74. Olbing H, Smellie JM, Jodal U et al. New renal scars in children with severe VUR: a 10-year study of randomized treatment. Pediatr Nephrol 2003; 18: 1128-1131.
75. Vianello A, Pignata G, Caldato C et al. Vesicoureteral reflux after kidney transplantation: clinical significance in the medium to long-term. Clin Nephrol 1997; 47: 356-361.
76. Pearson JC, Amend Jr WJ, Vincenti FG et al. Post-transplantation pyelonephritis: factors producing low patient and transplant morbidity. J Urol 1980; 123: 153-156.
77. Mastrosimone S, Pignata G, Maresca MC et al. Clinical significance of vesicoureteral reflux after kidney transplantation. Clin Nephrol 1993; 40: 38-45.
78. Schmaldienst S, Dittrich E, Horl WH. Urinary tract infections after renal transplantation. Curr Opin Urol 2002; 12: 125-130.
79. Rao KV, Andersen RC. Long-term results and complications in renal transplant recipients. Observations in the second decade. Transplantation 1988; 45: 45-52.
80. Grekas D, Thanos V, Dioudis C et al. Treatment of urinary tract infections with ciprofloxacin after renal transplantation. Int J Clin Pharmacol Ther Toxicol 1993; 31: 309-311.
81. Cuvelier R, Pirson Y, Alexandre GP et al. Late urinary tract infection after transplantation: prevalence, predisposition and morbidity. Nephron 1985; 40: 76-78.
82. Abbott KC, Swanson SJ, Richter ER et al. Late urinary tract infection after renal transplantation in the United States. Am J Kidney Dis 2004; 44: 353-362.
83. Muller V, Becker G, Delfs M et al. Do urinary tract infections trigger chronic kidney transplant rejection in man? J Urol 1998; 159: 1826-1829.
84. Dharnidharka VR, Agodoa LY, Abbott KC. Effects of urinary tract infection on outcomes after renal transplantation in children. Clin J Am Soc Nephrol 2007; 2: 100-106.
85. Dupont PJ, Psimenou E, Lord R et al. Late recurrent urinary tract infections may produce renal allograft scarring even in the absence of symptoms or vesicoureteric reflux. Transplantation 2007; 84: 351-355.
86. Tolkoff-Rubin NE, Cosimi AB, Russell PS et al. A controlled study of trimethoprim-sulfamethoxazole prophylaxis of urinary tract infection in renal transplant recipients. Rev Infect Dis 1982; 4: 614-618.
87. Munoz P. Management of urinary tract infections and lymphocele in renal transplant recipients. Clin Infect Dis 2001; 33(Suppl 1): S53-S57.
88. Preiksaitis JK. New developments in the diagnosis and management of posttransplantation lymphoproliferative disorders in solid organ transplant recipients. Clin Infect Dis 2004; 39: 1016-1023.
89. Caillard S, Dharnidharka V, Agodoa L et al. Posttransplant lymphoproliferative disorders after renal transplantation in the United States in era of modern immunosuppression. Transplantation 2005; 80: 1233-1243.
90. Cockfield SM. Identifying the patient at risk for post-transplant lymphoproliferative disorder. Transpl Infect Dis 2001; 3: 70-78.
91. Kew II CE, Lopez-Ben R, Smith JK et al. Postransplant lymphoproliferative disorder localized near the allograft in renal transplantation. Transplantation 2000; 69: 809-814.
92. Trofe J, Buell JF, Beebe TM et al. Analysis of factors that influence survival with post-transplant lymphoproliferative disorder in renal transplant recipients: the Israel Penn International Transplant Tumor Registry experience. Am J Transplant 2005; 5: 775-780.
93. Baid S, Cosimi AB, Tolkoff-Rubin N et al. Renal disease associated with hepatitis C infection after kidney and liver transplantation. Transplantation 2000; 70: 255-261.
94. Kamar N, Izopet J, Alric L et al. Hepatitis C virus-related kidney disease: an overview. Clin Nephrol 2008; 69: 149-160.
95. Cruzado JM, Gil-Vernet S, Ercilla G et al. Hepatitis C virus-associated membranoproliferative glomerulonephritis in renal allografts. J Am Soc Nephrol 1996; 7: 2469-2475.
96. Trimarchi HM, Gonzalez JM, Truong LD et al. Focal segmental glomerulosclerosis in a 32-year-old kidney allograft after 7 years without immunosuppression. Nephron 1999; 82: 270-273.
97. Cosio FG, Roche Z, Agarwal A et al. Prevalence of hepatitis C in patients with idiopathic glomerulopathies in native and transplant kidneys. Am J Kidney Dis 1996; 28: 752-758.
98. Baid S, Pascual M, Williams Jr WW et al. Renal thrombotic microangiopathy associated with anticardiolipin antibodies in hepatitis C-positive renal allograft recipients. J Am Soc Nephrol 1999; 10: 146-153.
99. Baid S, Cosimi AB, Farrell ML et al. Posttransplant diabetes mellitus in liver transplant recipients: risk factors, temporal relationship with hepatitis C virus allograft hepatitis, and impact on mortality. Transplantation 2001; 72: 1066-1072.
100. Delgado-Borrego A, Casson D, Schoenfeld D et al. Hepatitis C virus is independently associated with increased insulin resistance after liver transplantation. Transplantation 2004; 77: 703-710.
101. Basse G, Ribes D, Kamar N et al. Rituximab therapy for de novo mixed cryoglobulinemia in renal transplant patients. Transplantation 2005; 80: 1560-1564.
102. Hofland CA, Eron LJ, Washecka RM. Hemorrhagic adenovirus cystitis after renal transplantation. Transplant Proc 2004; 36: 3025-3027.
103. Friedrichs N, Eis-Hubinger AM, Heim A et al. Acute adenoviral infection of a graft by serotype 35 following renal transplantation. Pathol Res Pract 2003; 199: 565-570.
104. Keswani M, Moudgil A. Adenovirus-associated hemorrhagic cystitis in a pediatric renal transplant recipient. Pediatr Transplant 2007; 11: 568-571.
105. Yango Jr A, Morrissey P, Gohh R et al. Donor-transmitted parvovirus infection in a kidney transplant recipient presenting as pancytopenia and allograft dysfunction. Transpl Infect Dis 2002; 4: 163-166.
106. Eid AJ, Brown RA, Patel R et al. Parvovirus B19 infection after transplantation: a review of 98 cases. Clin Infect Dis 2006; 43: 40-48.
107. Murer L, Zacchello G, Bianchi D et al. Thrombotic microangiopathy associated with parvovirus B 19 infection after renal transplantation. J Am Soc Nephrol 2000; 11: 1132-1137.
108. Moudgil A, Nast CC, Bagga A et al. Association of parvovirus B19 infection with idiopathic collapsing glomerulopathy. Kidney Int 2001; 59: 2126-2133.
109. Wierenga KJ, Pattison JR, Brink N et al. Glomerulonephritis after human parvovirus infection in homozygous sickle-cell disease. Lancet 1995; 346: 475-476.
110. Marchand S, Tchernia G, Hiesse C et al. Human parvovirus B19 infection in organ transplant recipients. Clin Transplant 1999; 13: 17-24.
111. Moudgil A, Shidban H, Nast CC et al. Parvovirus B19 infection-related complications in renal transplant recipients: treatment with intravenous immunoglobulin. Transplantation 1997; 64: 1847-1850.